We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Julie
Kitcheman
medjki@leeds.ac.uk
Mrs
eortcliaison
NHM
eortcliaison@nihr.ac.uk
Dr
Jenny
Sherriff
Jenny.Sherriff@uhb.nhs.uk
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This study is looking at the use of a technique called stereotactic body radiation therapy (SBRT) as a treatment for people with rare oligometastatic cancers.
This study aims to find out whether adding SBRT to standard cancer treatment helps to better control this type of cancer from further spreading. Participants will either receive standard treatment or standard treatment plus SBRT. Whilst doctors think adding SBRT may work better against this type of cancer than standard treatment on its own, there is no proof of this yet, which is why this study is being done.
This study will take place in NHS sites in the UK as part of a wider international study. The study is sponsored and coordinated by the EORTC (European Organisation for Research and Treatment of Cancer), a non-profit organisation based in Brussels.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Radiotherapy;
You can take part if:
You may not be able to take part if:
• Primary cancer of prostate, breast, lung or colorectal • Serious medical comorbidities precluding radiotherapy: • These include interstitial lung disease in patients requiring thoracic radiation, Crohn’s disease in patients where the GI tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma • For patients with liver metastases, moderate/severe liver dysfunction (Child Pugh B or C) • Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets study dose constraints. For patients treated previously with radiation, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in the Radiation Therapy Quality Assurance (RTQA) Guidelines. All such cases should be discussed with one of the study coordinators • Brain metastases only, without extra-cerebral metastases • Malignant pleural effusion, malignant ascites, meningeal carcinomatosis and peritoneal carcinomatosis • Maximum size of 6 cm for lesions outside the brain, except: • Bone metastases over 5 cm may be included, if in the opinion of the local radiation oncologist it can be treated safely (e.g. rib, scapula, pelvis) • Clinical or radiologic evidence of symptomatic spinal cord compression. Patients can be eligible if spinal surgical resection has been performed, but the surgical site counts toward the total of up to 3 metastases. • Metastatic disease that invades any of the following: gastrointestinal tract (including oesophagus, stomach, small or large bowel), mesenteric lymph nodes, or disseminated skin metastases and lymphangiosis • Pregnant or breast feeding women • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mrs
eortcliaison
NHM
eortcliaison@nihr.ac.uk
Dr
Jenny
Sherriff
Jenny.Sherriff@uhb.nhs.uk
Julie
Kitcheman
medjki@leeds.ac.uk
The study is sponsored by European Organisation for Research and Treatment of Cancer and funded by European Organisation for Research and Treatment of Cancer .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49951
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
